Literature DB >> 12960125

Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.

Sheng Zhong1, Winnie Yeo, Mandy W Tang, Nathalie Wong, Paul B S Lai, Phillip J Johnson.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: The human Ras association domain family 1A gene (RASSF1A) is a newly isolated tumor suppressor gene. In this study, we analyzed the methylation status of the promoter region of RASSF1A using bisulfite sequencing and PCR-RFLP in four liver cancer cell lines (Hep3B, HepG(2), SK-HEP-1, and Huh-7) and a cohort of 43 hepatitis B virus-associated hepatocellular carcinoma (HCC) tissues and their corresponding nontumor tissue specimens.
RESULTS: The methylation of the CpG islands in the RASSF1A promoter was not detected in 4 samples of normal liver tissue or 10 samples of peripheral blood mononuclear cells from normal subjects. However, the CpG islands were completely methylated, and transcription of the RASSF1A was silenced in the four cell lines. Treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine reactivated the expression of RASSF1A in the Hep3B and HepG2 cells. In 41 of 43 (95%) HCC specimens studied, the promoter region of RASSF1A was intensively methylated at its CpG sites. Although heterogeneous methylation was also detected in 16 of the 23 (70%) corresponding nontumorous tissues analyzed, the level of methylation was significantly lower than in the corresponding tumor tissues.
CONCLUSIONS: HCC has the highest incidence of promoter methylation of RASSF1A among all malignancies yet reported suggesting that hypermethylation of the CpG island promoter of RASSF1A may play an important pathological role in this tumor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960125

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 2.  Environmental epigenetics and its implication on disease risk and health outcomes.

Authors:  Shuk-Mei Ho; Abby Johnson; Pheruza Tarapore; Vinothini Janakiram; Xiang Zhang; Yuet-Kin Leung
Journal:  ILAR J       Date:  2012

Review 3.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

4.  DNA methylation in hepatocellular carcinoma: what is the use?

Authors:  Jeroen Dekervel; Jos van Pelt; Chris Verslype
Journal:  Hepat Oncol       Date:  2015-11-06

5.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1.

Authors:  Xiaoying Zhang; Cai Guo; Xiwei Wu; Arthur X Li; Limin Liu; Walter Tsark; Reinhard Dammann; Hui Shen; Steven L Vonderfecht; Gerd P Pfeifer
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

7.  Detecting abnormal methylation of tumor suppressor genes GSTP1, P16, RIZ1, and RASSF1A in hepatocellular carcinoma and its clinical significance.

Authors:  Zhen Qu; Yong Jiang; Huan Li; DE-Cai Yu; Yi-Tao Ding
Journal:  Oncol Lett       Date:  2015-07-24       Impact factor: 2.967

8.  Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.

Authors:  Hector Hernandez-Vargas; Marie-Pierre Lambert; Florence Le Calvez-Kelm; Géraldine Gouysse; Sandrine McKay-Chopin; Sean V Tavtigian; Jean-Yves Scoazec; Zdenko Herceg
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

Review 9.  DNA methylation in hepatocellular carcinoma.

Authors:  Iris Tischoff; Andrea Tannapfe
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:  Winnie Yeo; Hyun C Chung; Stephen L Chan; Ling Z Wang; Robert Lim; Joel Picus; Michael Boyer; Frankie K F Mo; Jane Koh; Sun Y Rha; Edwin P Hui; Hei C Jeung; Jae K Roh; Simon C H Yu; Ka F To; Qian Tao; Brigette B Ma; Anthony W H Chan; Joanna H M Tong; Charles Erlichman; Anthony T C Chan; Boon C Goh
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.